Topas Therapeutics
A biotechnology company focused on developing products to address areas of major unmet need.
About Topas Therapeutics
Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s natural immunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering. Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies. Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
Company Facts
- Headquarters
- Hamburg
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00051_00100
- Funding Stage
- early_stage_venture
- Total Funding
- $67,662,073
- Last Funding Type
- series_b
- Last Funding Date
- 2021-07-29
- Website
- topas-therapeutics.comtopashome
Industries & Categories
Advanced Materials, Biotechnology, Chemical, Chemical Engineering
Social Links
Canonical: https://fsome.com/organization/topas-therapeutics-126029 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.